Anti-CD33 chimeric antigen receptor T cell therapy (Intrexon/ZIOPHARM Oncology)

N/A

Report date: 2022/09/01 20:01:19

Base Information

Drug NameAnti-CD33 chimeric antigen receptor T cell therapy (Intrexon/ZIOPHARM Oncology)
Drug Alias Nameautologous T cell therapy抗CD33嵌合抗原受体T细胞疗法（Intrexon/ZIOPHARM Oncology）CD33-CAR-T-cellsAnti-CD33 chimeric antigen receptor T cell therapy - ZIOPHARM/Intrexon
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsImmunologic cytotoxicityT lymphocyte replacements
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsHematologic NeoplasmsLymphomaLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesZiopharm Oncology IncIntrexon Corporation
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterIntrexon Corporation
Active IndicationsN/A
Inactive IndicationsHematologic NeoplasmsLymphomaLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A